#United States #Annual Meeting #Azitra #ATR-12 #Branford

Azitra, Inc. Announces Rescheduling of 2026 Annual Meeting

Azitra, Inc. (NYSE American: AZTR), a biopharmaceutical company specializing in innovative dermatological therapies, has recently made a crucial announcement regarding its upcoming annual stockholders' meeting. The company has opted to convene this meeting originally set for June 4, 2026, at 11:00 a.m. Eastern Time, but will adjourn immediately to provide additional time for shareholders to submit their proxy materials.

The rescheduled meeting will now take place virtually on June 15, 2026, at 11:00 a.m. Eastern Time. This strategic move was prompted by a minor delay in mailing proxy materials, ensuring that shareholders have ample opportunity to engage in the voting process.

Details for Shareholders

Azitra emphasizes that stockholders eligible to vote as of April 24, 2026, should actively participate by casting their votes on important proposals presented during the meeting. The company highlights the need for eligible shareholders who have not yet voted to reach out to their brokers or banks to ensure their votes are counted.

For those who have already cast their votes and wish to maintain their decisions, no action is required. Shareholders are encouraged to submit their proxies as soon as possible, with a deadline of June 15, 2026, at 10:59 a.m. Eastern Time for receiving votes.

Presenting several options for casting votes, Azitra offers shareholders the convenience of voting by mail through a pre-addressed proxy card, online via their dedicated website, or telephonically by calling a toll-free number provided on their proxy card. These options simplify the voting process, allowing shareholders to vote from their homes or anywhere convenient.

The proposals that will be discussed at the reconvened meeting mirror those initially presented at the scheduled 2026 annual meeting, ensuring all key matters are addressed adequately with shareholder input.

About Azitra and Its Mission

Azitra is in a pivotal phase of development, focusing on precision dermatological treatments. The company’s leading candidate, ATR-12, aims to treat Netherton syndrome, a rare and serious skin condition that currently lacks approved therapeutic options. The program has made strides towards clinical trials and represents a beacon of hope for patients and caregivers facing the challenges of this debilitating disease.

Azitra is also advancing another key project, ATR-04, addressing EGFR inhibitor-associated rashes, which affect a significant number of individuals undergoing cancer treatment. Both projects leverage a unique approach that includes engineered strains of bacteria and insights from artificial intelligence to develop effective and safe therapeutic interventions.

By prioritizing patient-centric solutions, Azitra is pioneering therapeutic advancements that hold the potential to transform lives. The company is actively working to bring innovative dermatological therapies to market, aiming to provide those affected by rare dermatological conditions with the treatment options they desperately need.

Conclusion

As Azitra prepares for its reconvened annual meeting, it urges all eligible stockholders to participate in the voting process to ensure their voices are heard in steering the company’s direction. The administrative measures taken reflect Azitra’s commitment to transparency and shareholder engagement, fostering an environment where all stakeholders can contribute meaningfully to the future of the company and the lives it seeks to improve.

For more information about Azitra, its products, and its initiatives, please visit Azitra's official website.